Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 19/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4129123 | 0.90 | P2RX7 (0.86) | P2RX7 | |
| SCHEMBL5336494 | 0.87 | P2RX7 (0.78) | P2RX7 | |
| SCHEMBL4129882 | 0.87 | P2RX7 (0.78) | P2RX7 | |
| SCHEMBL4129972 | 0.86 | P2RX7 (0.74) | P2RX7 | |
| SCHEMBL4139188 | 0.86 | P2RX7 (0.70) | P2RX7 | |
| SCHEMBL4129949 | 0.85 | P2RX7 (0.69) | P2RX7 | |
| SCHEMBL4122056 | 0.85 | P2RX7 (0.92) | P2RX7 | |
| Azd9056 SCHEMBL4126642 | 0.85 | P2RX7 (1.00) | P2RX7 | |
| SCHEMBL4124554 | 0.85 | P2RX7 (0.75) | P2RX7 | |
| Azd9056 SCHEMBL29364060 | 0.85 | P2RX7 (1.00) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176853-A1 | Adamantane derivatives | ALCARAZ LILIAN | 2009-07-09 | — | — | US | disclosed |
| US-20080139636-A1 | Adamantane derivatives | ASTRAZENECA AB. | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176853-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | P2RX7 1692/4885 |
| US-20080139636-A1 | Adamantane derivatives | ADAM33, ADAM17, BACE1 | P2RX7 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.